Pfiz­er scoops up Are­na and its S1P drug in $6.7B buy­out — chas­ing Bris­tol My­ers and cap­ping a lengthy biotech turn­around

When Bris­tol My­ers Squibb cel­e­brat­ed the ap­proval of ozan­i­mod — brand­ed Zeposia — in ul­cer­a­tive col­i­tis ear­li­er this year, the com­pa­ny tout­ed the first gas­troin­testi­nal in­di­ca­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER